Darglitazone
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
5-[(4-[3-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl)methyl]-1,3-thiazolidine-2,4-dione
|
|
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number | 141200-24-0 |
PubChem | CID: 60870 |
ChemSpider | 54854 |
UNII | AVP9C03Z3K |
ChEMBL | CHEMBL55624 |
Chemical data | |
Formula | C23H20N2O4S |
Molecular mass | 420.481 g/mol |
|
|
|
|
(what is this?) (verify) |
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.[1]
Its development was terminated on November 08, 1999.[2]
Synthesis
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
Categories:
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes with an unspecified ATC code
- Abandoned drugs
- Oxazoles
- Thiazolidinediones